Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators aim to investigate the effects of a telemonitoring and chatbot-based application of "Living well with COPD" (CAir) on health-related quality-of-life in patients with COPD.
The disease management programme "Living well with COPD" was developed to relieve symptoms and prevent exacerbations. It covers a disease self-management approach, educational topics, lifestyle coaching and physical activity advice.
Future implications should aim to make the intervention easily accessible for a broad spectrum of patients at scalable costs. Patients need an engaging communication platform which can inform, coach and even listen in between medical visits. The inclusion of a chatbot agent may provide this tailored feedback. The investogator's aim is to investigate the effects of a telemonitoring and chatbot-based application of "Living well with COPD" on health-related quality-of-life in patients with COPD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| chatbot-based intervention programme (intervention) | Experimental | Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the "Living well with COPD" programme (e.g. educational content, information on exercise training) to the patient. |
|
| Usual care group (control) | Other | Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CAir | Combination Product | The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 [2017], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified. |
| Measure | Description | Time Frame |
|---|---|---|
| Health-related quality-of-life (HrQoL) | St. George Respiratory Questionnaire (SGRQ). Scoring: Scores range from 0 to 100, with higher scores indicating more limitations. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Symptom burden | COPD Assessment Test (CAT). Scoring: Scores range from 0-40, with higher scores indicating more symptoms. | 3 months |
| Spirometry | Forced expiratory volume in one second (FEV1) in liters and percent predicted. |
Not provided
Inclusion Criteria:
• Diagnosed COPD according to GOLD-guidelines
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christian F Clarenbach, MD | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Zurich | Zurich | 8091 | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39735636 | Derived | Kohlbrenner D, Kuhn M, Klay A, Sievi NA, Muszynski M, Ivankay A, Gross CS, Asisof A, Brunschwiler T, Clarenbach CF. Hybrid Virtual Coaching and Telemonitoring in COPD Management: The CAir Randomised Controlled Study. Int J Chron Obstruct Pulmon Dis. 2024 Dec 24;19:2739-2750. doi: 10.2147/COPD.S487105. eCollection 2024. | |
| 33090112 |
Not provided
Not provided
upon reasonable request
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C011416 | carboxyaminoimidazole ribotide |
Not provided
Not provided
Not provided
We will perform a 2:1 randomised, two-arm, single (assessor)-blind, monocentric trial.
Not provided
Not provided
Not provided
|
| 3 months |
| Spirometry | Forced vital capacity (FVC) in liters and percent predicted. | 3 months |
| Accelerometry | Daily step count (number of steps) | 3 months |
| Functional exercise capacity | Six-minute walk test (6MWT) in meters walked. | 3 months |
| Functional exercise capacity | One-minute sit-to-stand test (1MSTS) in repetitions performed. | 3 months |
| Gross C, Kohlbrenner D, Clarenbach CF, Ivankay A, Brunschwiler T, Nordmann Y, V Wangenheim F. A Telemonitoring and Hybrid Virtual Coaching Solution "CAir" for Patients with Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2020 Oct 22;9(10):e20412. doi: 10.2196/20412. |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |